Spots Global Cancer Trial Database for Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
Study ID: NCT01924195
Conditions
Study Description
Brief Summary: Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of andvanced non-small cell lung cancer who failed two lines of chemotherapy
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Beijing chest hospital，capital medical university, Beijing, Beijing, China
Xinqiao Hospital, Third Military Medical University, Chongqing, Chongqing, China
Hunan Province Tumor Hospital, Changsha, Hunan, China
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Jilin province tumor hospital, Changchun, Jilin, China
Shandong Province Tumor Hospital, Jinan, Shandong, China
Chest hospital affiliated to Shanghai jiaotong university, Shanghai, Shanghai, China
Shanghai Changhai Hospital, Shanghai, Shanghai, China
West China Hospital,Sichuan University, Chengdu, Sichuan, China
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The first affiliated hospital,zhejiang university, Hangzhou, Zhejiang, China
Contact Details
Name: Bao hui Han, doctor
Affiliation: Chest hospital affiliated to Shanghai jiaotong university
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
